AB Science S.A. (ABSCF) Stock

About AB Science S.A.

AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors, designed for applications in both human and animal medicine. The company's flagship product is masitinib, a tyrosine kinase inhibitor currently undergoing extensive Phase III clinical trials for a diverse range of serious conditions. These include prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II trials for the treatment of Covid-19. Beyond masitinib, AB Science is advancing other therapeutic candidates, such as AB8939, a synthetic microtubule destabilizer intended for acute myeloid leukemia. Another compound, AB20001, is in Phase II investigation, assessing the safety and efficacy of masitinib combined with isoquercetin for hospitalized patients suffering from moderate to severe COVID-19. In Europe, masitinib is already commercially available for certain indications under the brand name Masivet. Established in 2001, AB Science S.A. maintains its corporate headquarters in Paris, France.

AB Science S.A. is headquartered in FR.

AB Science S.A. (ABSCF) stock trades at $1.12 with a market capitalization of $82.04M. The stock is valued at a price-to-earnings (P/E) ratio of -15.57, price-to-book of -2.60, price-to-sales of 38.19. Over the past 52 weeks the stock has ranged between $1.12 and $2.70, and currently trades 58.5% below its 52-week high.

On profitability, AB Science S.A. generates a return on equity (ROE) of 6.99%, return on capital employed of -12.53%, an operating margin of -103.66%, a net profit margin of -132.62%.

Official website: www.ab-science.com